IGC Pharma
23 hedge funds and large institutions have $1.19M invested in IGC Pharma in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 4 closing their positions.
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
8% more capital invested
Capital invested by funds: $1.11M → $1.19M (+$83.4K)
0.32% more ownership
Funds ownership: 3.39% → 3.71% (+0.32%)
8% less funds holding
Funds holding: 25 → 23 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$53.4K |
| 2 |
FW
FullCircle Wealth
Dallas,
Texas
|
+$41.5K |
| 3 |
VF
Virtu Financial
New York
|
+$30.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$26.2K |
| 5 |
Morgan Stanley
New York
|
+$6.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$66.1K |
| 2 |
Jane Street
New York
|
-$9.57K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$401 |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$284 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$15 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Fidelity Investments
Boston,
Massachusetts
| – | -$15 | -36 | Closed |
|
27
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$3 | -6 | Closed |
|
IGC Hedge Fund Activity: Q3 2024 in Review
23 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2024, worth a combined $1.19M — up 7.5% from $1.11M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IGC and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 9 added.
The largest buyer was Geode Capital Management, adding an estimated $53.4K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $66.1K sold.
- 23 institutional investors held IGC Pharma (IGC) as of Q3 2024, down from 25 in Q2 2024.
- Funds reported $1.19M of IGC Pharma stock for Q3 2024, up 7.5% quarter-over-quarter.
- 2 funds opened new IGC Pharma positions in Q3 2024 and 4 closed out, a net change of -2 holders.
- The largest IGC Pharma buyer in Q3 2024 was Geode Capital Management, an estimated $53.4K added.
- The largest IGC Pharma seller in Q3 2024 was Susquehanna International Group, an estimated $66.1K sold.
Based on aggregated 13F filings for Q3 2024.